Utility of @entity1904 , XXXX and white blood cells alone and in combination for the prediction of clinical outcomes in @entity497 .

@entity1 @entity1904 @entity497 @entity204 @entity1851
Abstract Background: The added value of biomarkers, such as @entity1904 (PCT), @entity1851 ( @entity1851 ), and white blood cells (WBC), as adjuncts to clinical risk scores for predicting the outcome of @entity1 with @entity497 ( @entity497 ) is in question. We investigated the prognostic accuracy of initial and follow-up levels of inflammatory biomarkers in predicting @entity204 and adverse clinical outcomes in a large and well-defined cohort of @entity497 @entity1 . Methods: We measured PCT, @entity1851 and WBC on days 1, 3, 5, and 7 and followed the @entity1 over 30 days. We applied multivariate regression models and area under the curve (AUC) to investigate associations between these biomarkers, the clinical risk score CURB-65, and clinical outcomes [i.e., @entity204 and intensive care unit (ICU) admission]. Results: Of 925 @entity1 with @entity497 , 50 @entity1 died and 118 @entity1 had an adverse clinical outcome. None of the initial biomarker levels significantly improved the CURB-65 score for mortality prediction. Follow-up biomarker levels showed significant independent association with mortality at days 3, 5, and 7 and with improvements in AUC. Initial PCT and @entity1851 levels were independent prognostic predictors of adverse clinical outcome, and levels of all biomarkers during the course of disease provided additional prognostic information. Conclusions: This study provides robust insights into the added prognostic value of inflammatory markers in @entity497 . @entity1904 , @entity1851 , and to a lesser degree WBC provided some prognostic information on @entity497 outcomes, particularly when considering their kinetics at days 5 and 7 and when looking at adverse clinical outcomes instead of mortality alone.
